At the news
? BEARISHIMPACT 6/10 PRESS-RELEASE filed Apr 27, 2026 at 16:17 ET
Oruka Therapeutics announced a $500M underwritten public offering of common stock and pre-funded warrants, with an additional $75M option for underwriters. The proceeds will support its clinical-stage pipeline for psoriasis and inflammatory diseases. The offering represents roughly 15% dilution at current market cap, which is a negative signal for near-term stock price.
- $500M underwritten public offering of common stock and pre-funded warrants
- Underwriters have a 30-day option to purchase up to an additional $75M of shares
- Leerink Partners, TD Cowen, Goldman Sachs, Stifel, and Guggenheim Securities are joint bookrunning managers
- Shelf registration statement (Form S-3) became effective on April 10, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access